Clinical benefits of autologous platelet concentrate in periodontal intrabony defects: A network meta‐analysis of randomized controlled trials

Abstract

This study aimed to compare clinical benefits of autologous platelet concentrate with other periodontal regenerative approaches in intrabony defects. An electronic and hand search of studies up to December 2022 was conducted. Randomized controlled trials with at least 6 months of follow‐up were identified to compare autologous platelet concentrates with enamel matrix derivative, bone graft, guided tissue regeneration, and open‐flap debridement. All approaches involved papilla preservation flap surgery. The outcomes included probing depth reduction, clinical attachment level gain, linear bone fill, and safety. A network meta‐analysis and meta‐regression were performed. Fifty‐seven studies were included in five network meta‐analyses. Autologous platelets concentrate and its adjunct treatments achieved significantly greater clinical and radiographic parameters than did open‐flap debridement, and had comparable or better performance than other regenerative treatments. Platelet‐rich fibrin showed superiority over platelet‐rich plasma in probing depth reduction at 6‐month follow‐up. Minimal pain and improved wound healing were observed in the treatments with autologous platelet concentrate. Meta‐regression showed that deeper baseline intrabony defects resulted in larger probing depth reductions, while smoking impaired the effectiveness of regenerative surgeries. Minimal invasive flap designs led to less effect of regenerative materials. Autologous platelet concentrate is a promising biomaterial in periodontal regeneration due to its convenience, safety, and biocompatibility characteristics.